Page 211 - Read Online

Alonso-Peña et al. Cancer Drug Resist 2019;2:680-709 I http://dx.doi.org/10.20517/cdr.2019.006 Page 707

and XPC in human hepatocellular carcinoma. J Hepatol 2005;43:288-93.
137. Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-
invasive urothelial carcinoma. Cancer Discov 2014;4:1140-53.
138. Sishc BJ, Davis AJ. The role of the core non-homologous end joining factors in carcinogenesis and cancer. Cancers (Basel) 2017;9:E81.
139. Yang S, Wang XQ. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance. BMC Cancer 2017;17:344.
140. Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol
2016;65:1031-42.
141. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001;1:68-76.
142. Ye S, Zhao XY, Hu XG, Li T, Xu QR, et al. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in
hepatocellular carcinoma. Oncol Rep 2017;37:2215-26.
143. Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, et al. Association of TP53 mutations with stem cell-like gene expression and
survival of patients with hepatocellular carcinoma. Gastroenterology 2011;140:1063-70.
144. Chan KT, Lung ML. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother
Pharmacol 2004;53:519-26.
145. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 2011;18:1487-99.
146. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial
translocation. J Biol Chem 2004;279:8076-83.
147. Gonzalez R, De la Rosa AJ, Rufini A, Rodriguez-Hernandez MA, Navarro-Villaran E, et al. Role of p63 and p73 isoforms on the cell
death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation. PLoS One 2017;12:e0174326.
148. Mundt HM, Stremmel W, Melino G, Krammer PH, Schilling T, et al. Dominant negative (DeltaN) p63alpha induces drug resistance in
hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem Biophys Res Commun 2010;396:335-41.
149. Kayhanian H, Smyth EC, Braconi C. Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol
2017;9:268-80.
150. Nutthasirikul N, Limpaiboon T, Leelayuwat C, Patrakitkomjorn S, Jearanaikoon P. Ratio disruption of the 133p53 and TAp53 isoform
equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Int J Oncol 2013;42:1181-8.
151. Nutthasirikul N, Hahnvajanawong C, Techasen A, Limpaiboon T, Leelayuwat C, et al. Targeting the 133p53 isoform can restore
chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells. Int J Oncol 2015;47:2153-64.
152. Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, et al. Next-generation sequencing survey of biliary tract cancer reveals the association
between tumor somatic variants and chemotherapy resistance. Cancer 2016;122:3657-66.
153. Namwat N, Amimanan P, Loilome W, Jearanaikoon P, Sripa B, et al. Characterization of 5-fluorouracil-resistant cholangiocarcinoma
cell lines. Chemotherapy 2008;54:343-51.
154. Soung YH, Lee JW, Kim SY, Sung YJ, Park WS, et al. Caspase-8 gene is frequently inactivated by the frameshift somatic mutation
1225_1226delTG in hepatocellular carcinomas. Oncogene 2005;24:141-7.
155. Ahn SM, Jang SJ, Shim JH, Kim D, Hong SM, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and
FGF19 aberrations for patient stratification. Hepatology 2014;60:1972-82.
156. Wattanawongdon W, Hahnvajanawong C, Namwat N, Kanchanawat S, Boonmars T, Jearanaikoon P, et al. Establishment and
characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Int J Oncol 2015;47:398-410.
157. Wang Z, Sheng YY, Gao XM, Wang CQ, Wang XY, et al. Beta-catenin mutation is correlated with a favorable prognosis in patients with
hepatocellular carcinoma. Mol Clin Oncol 2015;3:936-40.
158. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular
carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-70.
159. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, et al. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma
is associated with increased cell proliferation. Am J Pathol 1999;155:703-10.
160. Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, et al. Expression and prognostic roles of beta-catenin in hepatocellular
carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002;8:450-6.
161. Kan Z, Zheng H, Liu X, Li S, Barber TD, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.
Genome Res 2013;23:1422-33.
162. Yokoyama M, Ohnishi H, Ohtsuka K, Matsushima S, Ohkura Y, et al. KRAS mutation as a potential prognostic biomarker of biliary
tract cancers. Jpn Clin Med 2016;7:33-9.
163. Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, et al. K-Ras mutation and amplification status is predictive of resistance and high basal
pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. Mol Oncol 2017;11:1130-42.
164. Yu C, Wang X, Huang L, Tong Y, Chen L, et al. Deciphering the spectrum of mitochondrial DNA mutations in hepatocellular carcinoma
using high-throughput sequencing. Gene Expr 2018;18:125-34.
165. Kawamura N, Nagai H, Bando K, Koyama M, Matsumoto S, et al. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic
inactivation of both alleles in tumors. Jpn J Cancer Res 1999;90:413-8.
166. Fujiwara Y, Hoon DS, Yamada T, Umeshita K, Gotoh M, et al. PTEN / MMAC1 mutation and frequent loss of heterozygosity identified
in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res 2000;91:287-92.
167. Ho DWH, Chan LK, Chiu YT, Xu IMJ, Poon RTP, et al. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour
and treatment implication. Gut 2017;66:1496-506.